



## Prince William Cardiology Associates

Christopher J. Leet, MD, FACC  
Morton E. Kalus, Jr., MD, FACC

Nadim A. Geloo, MD  
Michelle A. Webb, MD

November 25, 2004

Licensing Assistance Section  
Nuclear Medicine Safety Branch  
Division of Radiation Safety and Safeguards  
U.S. Nuclear Regulatory Commission, Region I  
475 Allendale Road  
King of Prussia, PA 19406-1415

RE: Amendment Application  
Prince William Cardiology  
License Number: 45-30929-01

03036615

Dear License Reviewer:

Please amend our byproduct material license to add Nadim Geloo, M.D. as an authorized user for all materials and procedures approved on our current license. Dr. Geloo is currently listed as an authorized user on the license issued to Fauquier Hospital (License Number: 45-19484-01). Please refer to this document for confirmation of training and experience.

If additional information is required, please contact Michael Lairmore or myself. Mr. Lairmore may be reached at (201) 447-3303.

We thank you in advance for your assistance with this licensing action.

Sincerely,

Morton E. Kalus, M.D.  
Radiation Safety Officer

136088

NMSS/RGNI MATERIALS-002

8569-B Sudley Road, Manassas, VA 20110  
Telephone: (703) 369-5959 Fax: (703) 369-7473

380 Hospital Drive, Warrenton, VA 20186  
Telephone: (540) 347-9898 Fax: (540) 347-4571

REC'D IN LAT

DEC - 6 2004

**Attachment A**

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<b>Licensee</b>  1. Fauquier Hospital  2. 500 Hospital Drive Warrenton, Virginia 20186	In accordance with the letter dated <b>November 10, 2003</b> 3. License No. 45-19484-01 is amended in its entirety to read as follows: 4. <b>Expiration Date: August 31, 2011</b> 5. <b>Docket No: 030-17773</b>
---	---

<b>6. Byproduct, source, and/or special nuclear material</b>  A. Any byproduct material permitted by 10 CFR 35.100  B. Any byproduct material permitted by 10 CFR 35.200  C. Gadolinium 153	<b>7. Chemical and/or physical form</b>  A. Any  B. Any  C. Sealed source (DuPont Merck Model NES-8412; North American Scientific Model MED 3601)	<b>8. Maximum amount that licensee may possess at any one time under this license</b>  A. As needed  B. As needed  C. 37 gigabecquerels (GBq) (1 curie) total; no single source to exceed 11.1 GBq (300 millicuries)
---	---	--

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. For possession and use in ADAC Laboratories "Vantage" Nonuniform Attenuation Correction System in gamma cameras for imaging purposes. For storage in a shipping cask pursuant to source exchange.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
45-19484-01Docket No.  
030-17773Amendment No.  
22**CONDITIONS**

10. Licensed material may be used or stored only at the licensee's facilities located at Fauquier Hospital, 500 Hospital Drive, Warrenton, Virginia.
11. The Radiation Safety Officer (RSO) for this license is James R. Koepke, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UserMaterial and Use

Toby Louis Brown, M.D.	35.100; 35.200
Keith Chu, M.D.	35.200
Linda H. Davis-Daniel, M.D.	35.100; 35.200
Mohammad R. Ghafouri, D.O.	35.200
Ravi M. Giyanani, M.D.	35.100; 35.200
Keith Hellems, M.D.	35.100; 35.200
Todd H. Hillman, M.D.	35.100; 35.200
James R. Koepke, M.D.	35.100; 35.200
Douglas J. Markert, M.D.	35.100; 35.200
Philip N. Massey, M.D.	35.100; 35.200
Stephen L. Miller, M.D.	35.100; 35.200
Margaret M. Sanders, M.D.	35.100; 35.200

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
45-19484-01Docket No.  
030-17773Amendment No.  
22Authorized UserMaterial and Use

Duyanh T. Vu, M.D.	35.100; 35.200
David R. Weber, M.D.	35.100; 35.200
Patrick F. Zazzaro, M.D.	35.100; 35.200
Michelle A. Webb, M.D.	35.200
Jennifer T. Wargo, M.D.	35.100; 35.200
David M. Perlmutter, M.D.	35.100; 35.200
Maria E. Pace, M.D.	35.100; 35.200
Pamela M. Phillips, M.D.	35.100; 35.200
Nadim Geloo, M.D.	35.200
Hamid Taheri, M.D.	35.200
Shahram Yazdani, M.D.	35.200
Hassan Tabandeh, M.D.	35.200
Michael B. Robins, M.D.	35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License No.  
45-19484-01Docket No.  
030-17773Amendment No.  
22

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated October 25, 1990

B. Letters dated:


- 1) April 25, 1991 [commitment to RG 10.8, App. O]
- 2) October 5, 1998 [add Gd-153 for use in ADAC Vantage System]
- 3) January 24, 2001 [add Drs. Giyanani and Vu; remove old hot lab; new RSO (Dr. Weber)]
- 4) April 9, 2001 [additional info re: training and experience for Drs. Giyanani and Vu]
- 5) April 11, 2001 [renewal of license]
- 6) April 17, 2001 [fax re: additional info supporting release of old hot lab]
- 7) September 5, 2002 [add 5 users (Drs. Webb, Wargo, Perlmutter, Pace & Phillips; delete user (Dr. Clarke))]
- 8) December 5, 2002 [add 3 users (Drs. Geloo, Taheri & Shahram); change RSO (Dr. Koepke); updated for Part 35 revisions]
- 9) November 10, 2003 [add users (Drs. Tabandeh & Robins)]

FOR THE U. S. NUCLEAR REGULATORY COMMISSION

JAN 21 2004

DATE

BY



Bryan A. Parker  
Nuclear Materials Safety Branch 3  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406-1415

This is to acknowledge the receipt of your letter/application dated

11/25/2004, and to inform you that the initial processing which includes an administrative review has been performed.

☒ Revised. 45-30829-01  
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 136088.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.

BETWEEN: : (FOR LFMS USE)  
: INFORMATION FROM LTS  
: -----  
:   
License Fee Management Branch, ARM : Program Code: 02201  
and : Status Code: 0  
Regional Licensing Sections : Fee Category: 7C  
: Exp. Date: 20140831  
: Fee Comments: \_\_\_\_\_  
: Decom Fin Assur Req'd: \_  
: ::

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED

Applicant/Licensee: PRINCE WILLIAM NUCLEAR CARDIOLOGY  
Received Date: 20041206  
Docket No: 3036615  
Control No.: 136088  
License No.: 45-30929-01  
Action Type: Amendment

2. FEE ATTACHED

Amount: \_\_\_\_\_  
Check No.: \_\_\_\_\_

3. COMMENTS

Signed M.A. Perkins  
Date 12/10/2004

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /\_\_\_/)

1. Fee Category and Amount: \_\_\_\_\_

2. Correct Fee Paid. Application may be processed for:

Amendment \_\_\_\_\_  
Renewal \_\_\_\_\_  
License \_\_\_\_\_

3. OTHER \_\_\_\_\_  
\_\_\_\_\_

Signed \_\_\_\_\_  
Date \_\_\_\_\_